Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
- Conditions
- Overweight or Obesity
- Interventions
- Other: Matching Placebo
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Terns, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06854952
- Locations
- 🇺🇸
FALCON Research Site, Arlington, Virginia, United States
CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
- Conditions
- Chronic Myeloid Leukemia, Chronic PhaseChronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Terns, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06163430
- Locations
- 🇺🇸
UC Irvine Health, Orange, California, United States
🇺🇸Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States
🇺🇸Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Terns, Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT05415722
- Locations
- 🇺🇸
Site 1017: The Institute for Liver Health dba Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Site 1018: Arizona Liver Health, Tucson, Arizona, United States
🇺🇸Site 1004 Southern California Research Center, Coronado, California, United States
AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Other: Placebo
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Terns, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04897594
- Locations
- 🇺🇸
Terns Clinical Study Site 1018, Tucson, Arizona, United States
🇺🇸Terns Clinical Study Site 1024, Tucson, Arizona, United States
🇺🇸Terns Clinical Study Site 1004, Coronado, California, United States
LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Other: Placebo
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Terns, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT04328077
- Locations
- 🇺🇸
Terns Clinical Study Site 1017, Chandler, Arizona, United States
🇺🇸Terns Clinical Study Site 1018, Tucson, Arizona, United States
🇺🇸Terns Clinical Study Site 1024, Tucson, Arizona, United States
News
NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies
• The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. • This growth is fueled by the introduction of novel therapies targeting NASH, with several drugs in Phase II and Phase III clinical trials showing promise for improving treatment outcomes. • Key players such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Novo Nordisk are actively developing innovative treatments, contributing to a dynamic and competitive market landscape. • The increasing prevalence of NASH and the growing understanding of its pathophysiology are driving the demand for effective therapies, creating opportunities for pharmaceutical companies.